Meetings of the Minds 2002 | Research & Development | SENJU Pharmaceutical

Meetings of the Minds2002

XV International Congress of Eye Research (ICER)

  • DAY: to be released
  • Place:Geneva, Switzerland
  • ①○Emi Nakajima, Chiho Fukiage, Mitsuyoshi Azuma, T.R. Shearer
    ②○Takeshi Nakajima, Yoshiyuki Tamada, Emi Nakajima, Chiho Fukiage, Mitsuyoshi Azuma, T.R. Shearer

XVIIth International Symposium on Medicinal Chemistry

  • DAY: to be released
  • Place:Barcelona, Spain
  • Exploration of Peptidyl Hydrazones as Water-Soluble Calpain Inhibitors
  • Masayuki Nakamura and Jun Inoue

Controlled Release Society 29th Annual Meeting

  • DAY: to be released
  • Place:Seoul, KORIA
  • Ocular Bioavailability of Timolol Improved by Sorbic Acid
  • M. Higashiyama, K. Inada, A. Ohtori, K. Tojo

2004 FASEB Summer Research Conferences
“Biology of the Calpains in Health and Disease”

  • DAY: to be released
  • Place:Tucson, AZ
  • ①Involvement of calpain in retinopathy
    ②Involvement of calpain in retinal damage induced by elevated intraocular pressure in the rat
  • ①Mitsuyoshi Azuma1,2, Yoshiyuki Tamada1, Chiho Fukiage1, Takeshi Nakajima1, Emi Nakajima1,2 and Thomas R. Shearer2
    1 Senju Pharmaceutical Co. Ltd., 2 Oregon Health & Science University
    ②Emi Nakajima1,2, Yoshiyuki Tamada1,Mitsuyoshi Azuma1,2, and Thomas R. Shearer2
    1 Senju Pharmaceutical Co. Ltd., 2 Oregon Health & Science University

Association for Research in Vision and Ophthalmology (ARVO) 2002 Annual Meeting

  • DAY: to be released
  • Place:Fort Lauderdale, Florida, U.S.A.
  • ①Effect of Polyphenol for Rabbit Corneal Epithelium Storage
    ②Studies on Intraocular Penetration of Ophthalmic Solution by Use of Cyclodextrins for Anti-Cataract Therapeutic Agent
    ③Phosphorylation of Lens-Specific Calpain Lp82: Possible Regulatory Mechamism?
    ④Cleavage of p35, Regulator of CDK5, to p25 by Calpain in Retinal Cell Death
    ⑤Function of Retina-Specific Calpain Rt88 (Splice Variant of p94)
    ⑥Changes in Gene Expression in the Lens Epithelial Cells from Selenite Injected Rats
    ⑦Contribution of Ubiquitous Calpains to Cataractgenesis in Spontaneously Diabetic WBN/Kob Rat
    ⑧Crystallins Proteolyzed by Lens-Specific Calpain Lp82 Are Susceptible to Light Scattering
  • ①M.Tsuzuki, C.Sotozono, T.Nakamura, C.Mochida, Y.Ban, Y.Sano, S.Kinoshita
    ②M.Yamaguchi, M.Nakamura, J.Inoue
    ③T.R. Shearer, H. Ma, M. Azuma
    ④E. Nakajima, Y. Tamada, C. Fukiage, M. Azuma, T.R. Shearer
    ⑤C. Fukiage, M. Azuma, T. Nakajima, K. Mizutani, T.R. Shearer
    ⑥T. Nakajima, E. Nakajima, C. Fukiage, M. Azuma, T.R. Shearer
    ⑦M. Azuma, K. Mizutani, C. Fukiage, T.R. Shearer
    ⑧S. Daibo, C. Fukiage, Y. Tamada, N.E. Forsberg, M.K. Duncan, M. Azuma,T.R. Shearer

4th International Symposium on Ocular Pharmacology and Pharmaceutics (4th ISOPP)

  • DAY: to be released
  • Place:Seville, SPAIN

<< Sponsored Product Session >>
Date: 09:00 - 09:45 a.m. on Friday, March 1st, 2002 at Hall A in Hotel Alfonso XIII
Chairpersons: Hidetoshi Yamashita, M.D.(Prof. of Yamagata Univ. Yamagata, JAPAN)
Atsushi Okumura, Ph.D.(Senior Director of Senju Pharmaceutical, Osaka, JAPAN)

Oral Presentations:
 ・SJA6017   C. Fukiage
  Potential for therapeutic use of calpain inhibitor SJA6017 against ocular diseases
 ・Y-39983   H. Tokushige
  Therapeutic potential of Rho-associated protein kinase inhibitor (Y-39983) in Glaucoma
 ・BRONUCK    M. Wada
  BRONUCK - the most efficient NSAID: Interim safety and efficacy - post marketing analysis in Japan

new | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999